The Food and Drug Administration (FDA), which regulates food and medication in the US, has given the green light to continue with Phase 3 of the ANG1005’s clinical trials, a new anti-cancer agent created as part of UQAM’s Chair in Cancer Prevention and Treatment research. "Continuing clinical trials mean that ANG1005 will be tested as a new anti-cancer treatment," Borhane Annabi, Professor in the Department of Chemistry and Chairholder proudly says. "I was fortunate to have been a privileged witness to the development of the drug and the emergence of such a treatment strategy,” he continues. “This demonstrates the excellence of biomedical research that takes place at UQAM."
Laboratory work has contributed to a better understanding of the functioning of the blood-brain barrier and the biology of brain tumors, leading to the development of drugs that possess the ability to overcome this barrier. "Thus, targeting of tumors or brain metastases may be considered, which led to the development of peptide therapeutic conjugates by the Montreal-based company Angiochem."
The clinical potential of this strategy has made it possible to combine one of these peptides with paclitaxel (ANG1005), a powerful chemotherapy drug. ANG1005’s Phase 2 clinical results were presented in the United States in early June at the prestigious American Society of Clinical Oncology Congress in Chicago. "This compound - developed by Angiochem - has been shown to have significant clinical benefits, both intracranial and extracranial, in the treatment of leptomeningeal carcinomatosis in patients with breast cancer and with recurrent brain metastases,”confirms Borhane Annabi. “These patients experienced improved clinical symptoms and longer survival outlooks than in untreated patients."
Following the FDA’s positive recommendations, Angiochem will continue the clinical development of ANG1005 for patients with this form of breast cancer and for whom no treatment is currently available.
Translated from the following article: https://www.actualites.uqam.ca/2016/nouveau-traitement-anticancer